Loading patent…
Assigneeargenx BV
InventorsChristophe Blanchetot, Kevin Budding, Erik Hack, Karen Silence, Inge Van De Walle, Ludo Van Der Pol, Peter Boross
Estimating the term…
The present invention relates to a method of treating a paraproteinemic neuropathy in a subject by administering to the subject an antagonist of the complement system. The antagonist inhibits the complement system upstream of complement factor C5. More specifically, the antagonist may be an antibody or an antigen-binding fragment thereof that blocks or inhibits the complement system by inhibiting the C2b domain of complement factor C2. The paraproteinemic neuropathies that may be treated include, in particular, multifocal motor neuropathy (MMN), chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barre syndrome (GBS).
A method of treating a paraproteinemic neuropathy in a subject, the method comprising administering to the subject an anti-C2 antibody or antigen-binding fragment thereof comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein the VH comprises the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.